Back to search

Peptide record

TPDB04339

Antibacterial Anticancer Hemolysis Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB04339
Antibacterial Anticancer Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia PD_Hemolysis
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, Hemolysis, and other sources) peptide sequence curated from AntiBP3, Peptipedia, and PD_Hemolysis, with an available 3D structural model.
Sequence
KWCVYAYVKVKGVLVKYKKCW
Physicochemical Analysis
C127H195N29O25S2
RNDEQHIMFPST
K
2592.24
10.11
6
0
12
+6
-1.43
0.100
92.38
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
15595
601.60
5
Residue Composition
number
1
A
0
R
0
N
0
D
2
C
0
E
0
Q
1
G
0
H
0
I
1
L
6
K
0
M
0
F
0
P
0
S
0
T
2
W
3
Y
5
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 1 K: 6 M: 0 F: 0 P: 0 S: 0 T: 0 W: 2 Y: 3 V: 5
Chemical Descriptors
21
C127H195N29O25S2
2592.24
10.11
+6
-1.43
0.100
Evidence Records 7 records
Evidence 1 Activity

Activity

MIC
Antibacterial
1-2 µM

Target

E.coli ML35p or ATCC 25922 or M15

Source & Reference

NA

Other

active against Gram- E.coli ML35p or ATCC 25922 or M15 (MIC 1-2 uM), P. aeruginosa ATCC 27853 or clinical c.i. (MIC 1-4 uM), A. baumanii c.i. (MIC 1 uM), Gra
Evidence 2 Activity

Activity

MIC
Antibacterial
2 µM

Target

L. monocytogenes EGD

Source & Reference

NA

Other

. aeruginosa ATCC 27853 or clinical c.i. (MIC 1-4 uM), A. baumanii c.i. (MIC 1 uM), Gram+ L. monocytogenes EGD (MIC 2 uM), S. aureus 710A or ATCC 25923 or MRSA ATCC 33591 or clinical c.i. (MIC 2-4 uM), S. interm
Evidence 3 Activity

Activity

MIC
Antibacterial
4 µM

Target

S. intermidius

Source & Reference

NA

Other

MIC 2 uM), S. aureus 710A or ATCC 25923 or MRSA ATCC 33591 or clinical c.i. (MIC 2-4 uM), S. intermidius (MIC 4 uM).
Evidence 4 Activity

Activity

15% Hemolysis
Toxicity
10.1 µM
Hemolytic Cytotoxic
15% Hemolysis | 10.1 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Redesigning Arenicin-1, an Antimicrobial Peptide from the Marine Polychaeta Arenicola marina, by Strand Rearrangement or Branching, Substitution of Specific Residues, and Backbone Linearization or Cyclization. | Mar Drugs | 2019
Evidence 5 Activity

Activity

50% Hemolysis
Toxicity
63 µM
Hemolytic Cytotoxic
50% Hemolysis | 63 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Redesigning Arenicin-1, an Antimicrobial Peptide from the Marine Polychaeta Arenicola marina, by Strand Rearrangement or Branching, Substitution of Specific Residues, and Backbone Linearization or Cyclization. | Mar Drugs | 2019
Evidence 6 Activity

Activity

% Hemolysis
Toxicity
15 %
Hemolytic Cytotoxic
Hemolytic_activity: Human erythrocytes: 15% Hemolysis=10.1 µM 50% Hemolysis=63 µM | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Mar Drugs. 2019 Jun 23 17(6):376.
Evidence 7 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis